证券日报网讯沃尔核材11月24日在互动平台回答投资者提问时表示，公司H股发行上市有益于公司的长 远发展，一方面有利于公司拓宽融资渠道，为公司在技术研发、产能建设以及海外市场布局等方面的持 续投入提供有力支持，以增强公司核心竞争力；另外一方面有利于推进公司国际化战略，提升公司国际 品牌形象。公司将综合考虑各方因素，合理安排相关工作。 （文章来源：证券日报） ...

Core Viewpoint - Guangdong Lingyi Intelligent Manufacturing Co., Ltd. has submitted an application for the issuance of H-shares and listing on the Hong Kong Stock Exchange, indicating a strategic move to access international capital markets [1][2]. Group 1: Application Details - The application for the H-share issuance was submitted on November 20, 2025, and the related materials were published on the Hong Kong Stock Exchange website on the same day [1]. - The issuance will be limited to qualified overseas investors and domestic qualified investors who are authorized to conduct overseas securities investments under Chinese laws [1][2]. Group 2: Regulatory Considerations - The issuance and listing are subject to approvals from the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, and the Hong Kong Stock Exchange, indicating that the process involves multiple regulatory layers [2]. - The company will not publish the application materials on domestic stock exchange websites or media, but will provide links for domestic investors to access the information on the Hong Kong Stock Exchange website [1][2].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 苏州纳芯微电子股份有限公司（以下简称"公司"）正在进行申请境外发行股份（H股）并在香港联合交 易所有限公司（以下简称"香港联交所"）主板上市（以下简称"本次发行H股及上市"或"本次发行"）的 相关工作。 2025年4月25日，公司向香港联合交易所递交了本次发行上市的申请，并于同日在香港联合交易所网站 刊登了本次发行并上市的申请资料。按照本次发行上市的时间安排并根据香港联交所的相关规定，公司 于2025年10月27日向香港联交所重新递交了本次发行的申请，并于同日在香港联交所网站刊登了本次发 行的申请资料。具体内容详见公司分别于2025年4月28日、2025年10月29日在上海证券交易所官方网站 （www.sse.com.cn）披露的《关于向香港联合交易所有限公司递交H股发行及上市的申请并刊发申请资 料的公告》（公告编号：2025-023）、《关于重新向香港联合交易所有限公司递交H股发行及上市的申 请并刊发申请资料的公告》（公告编号：2025-040）。 2025年10月21日，公司 ...

Group 1 - The board of directors of Suzhou Naxin Microelectronics Co., Ltd. held its 21st meeting of the third session on November 18, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][4] - The board approved the proposal regarding the global offering of H shares and related arrangements for listing on the Hong Kong Stock Exchange, authorizing relevant personnel to handle specific matters related to the issuance and listing [2][5] - The board also approved the confirmation and commitment related to the H share issuance, ensuring compliance with relevant legal requirements for the prospectus [5][6] Group 2 - The board approved amendments to the internal governance system applicable after the H share issuance, allowing the chairman and authorized personnel to make necessary adjustments to the governance documents based on legal and regulatory requirements [7][8] - The revised internal governance system will take effect upon the listing of the H shares on the main board of the Hong Kong Stock Exchange, automatically invalidating the current governance system [7][8]

证券代码：688506 证券简称：百利天恒 公告编号：2025-083 鉴于目前的市场情况，公司决定延迟本次H股的全球发售及上市，并于2025年11月12日在香港联交所网 站发布公告。 因本次拟发行的股份为H股，本次发行股份的认购对象仅限于符合相应条件的境外投资者及依据中国相 关法律法规有权进行境外证券投资管理的境内证券经营机构和合格境内机构投资者及其他符合监管规定 的投资者，公司将不会在境内证券交易所的网站和符合监管机构规定条件的媒体上刊登公告内容，相关 公告内容可于香港联交所网站进行查询，具体的查询链接具体如下： 中文： https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1112/2025111200239_c.pdf 英文： https://www1.hkexnews.hk/listedco/listconews/sehk/2025/1112/2025111200238.pdf 四川百利天恒药业股份有限公司 关于发行H股并上市的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性 ...

Core Points - Transsion Holdings (688036) closed at 65.85 yuan on November 12, 2025, down 2.29% from the previous trading day, with a total market capitalization of 75.806 billion yuan [1] - The company announced its first extraordinary general meeting of 2025, scheduled for November 28, 2025, to discuss several key proposals, including the issuance of H-shares and listing on the Hong Kong Stock Exchange [1] Group 1: Stock Performance - The stock opened at 67.28 yuan, reached a high of 67.29 yuan, and a low of 65.77 yuan, with a trading volume of 6.58 billion yuan and a turnover rate of 0.86% [1] Group 2: Upcoming Shareholder Meeting - The extraordinary general meeting will combine on-site and online voting, addressing proposals such as issuing H-shares, amending the company’s articles of association, electing independent directors, and appointing an auditing firm for the H-share issuance [1] - The record date for shareholders to participate in the meeting is November 24, 2025 [1]

Core Viewpoint - Sichuan Baili Tianheng Pharmaceutical Co., Ltd. is in the process of issuing H-shares and listing on the Hong Kong Stock Exchange, with various steps completed in the application and approval process [1][2][3][4]. Group 1: Application and Approval Process - The company submitted its application for H-share issuance to the Hong Kong Stock Exchange on July 10, 2024, and published the application materials on the same day [2]. - The company resubmitted its application on January 21, 2025, and September 29, 2025, in accordance with the Hong Kong Stock Exchange's regulations [2]. - On December 11, 2024, the China Securities Regulatory Commission confirmed the company's application for overseas issuance and listing [3]. - The Hong Kong Stock Exchange's listing committee held a hearing on December 19, 2024, to review the company's application [3]. Group 2: H-share Offering Details - The total number of H-shares to be issued is 8,634,300, with 863,500 shares allocated for public offering in Hong Kong, representing approximately 10% of the total, and 7,770,800 shares for international offering, representing approximately 90% [6]. - The price range for the H-share issuance is preliminarily set between HKD 347.50 and HKD 389.00 [6]. - The public offering in Hong Kong commenced on November 7, 2025, and is expected to conclude on November 12, 2025, with the issuance price to be announced by November 14, 2025 [6]. - The H-shares are anticipated to be listed and commence trading on the Hong Kong Stock Exchange on November 17, 2025 [6].

Core Viewpoint - Shantui Construction Machinery Co., Ltd. has shown stable revenue growth and significant profit increase in Q3 2025, alongside ongoing stock buyback and H-share issuance preparations [3][4][5]. Group 1: Q3 Performance - In Q3 2025, the company achieved a revenue of 10.488 billion yuan, a year-on-year increase of 2.36% [3] - The net profit attributable to shareholders was 838 million yuan, reflecting a year-on-year growth of 15.67% [3] - The net profit after deducting non-recurring gains and losses was 823 million yuan, with a year-on-year increase of 24.40% [3] - Basic earnings per share were 0.5595 yuan, up 15.84% year-on-year [3] Group 2: Stock Buyback Progress - As of October 31, 2025, the company has repurchased 10,762,650 shares, accounting for 0.72% of the total share capital [4] - The repurchase price ranged from 8.64 yuan to 9.74 yuan per share [4] - The company plans to continue the buyback based on market conditions and will fulfill information disclosure obligations [4] Group 3: H-Share Issuance Project - The company is progressing with its H-share issuance and listing on the Hong Kong Stock Exchange [5] - Key milestones include receiving approval from the controlling shareholder on August 14, 2025, and submitting the IPO application to the Hong Kong Stock Exchange on August 28, 2025 [5] - The company has responded to supplementary material requests from the China Securities Regulatory Commission and is preparing responses to inquiries from the Hong Kong Stock Exchange [5] Group 4: On-Site Visit - The research team conducted an on-site visit to the company's exhibition hall and main engine factory, gaining insights into the product matrix and application scenarios [6] - The visit provided a comprehensive understanding of the company's operational performance, capital operations, and strategic planning [6]

Meeting Overview - The second extraordinary general meeting of shareholders was held on October 17, 2025, at the Innovation Technology Building in Shenzhen [5] - The meeting was convened by the board of directors and chaired by Chairman Deng Xueqin, utilizing a combination of on-site and online voting methods [2][3] Attendance - All 8 current directors attended the meeting, along with the board secretary Wang Xiaoqin and other senior management personnel [3] Resolutions Passed - The following key resolutions were approved during the meeting: - Proposal for the company to issue H-shares and list on the Hong Kong Stock Exchange [4] - Various aspects of the H-share issuance, including types and par value, issuance timing, method, scale, pricing, and target investors, were all approved [6][7] - The proposal to convert the company into an overseas fundraising joint-stock company was approved [7] - The fundraising usage plan for the H-share issuance was approved [7] - Authorization for the board of directors and its authorized personnel to handle matters related to the H-share issuance was approved [7] - Profit distribution plan prior to the H-share issuance was approved [7] - Amendments to the company's articles of association and related rules post-H-share issuance were approved [8] Legal Verification - The meeting was witnessed by Beijing Jiayuan Law Firm, confirming that the convening, procedures, and voting were in compliance with relevant laws and regulations [10]

Core Points - The company has announced the repurchase and cancellation of 281,500 shares from the 2024 employee stock ownership plan due to the departure of 9 holders and 4 holders not meeting performance targets, at a price of 6.13 yuan per share [1][2] - Following the repurchase, the total number of shares will decrease from 1,064,996,294 to 1,064,714,794, and the registered capital will also reduce correspondingly [2] Group 1: Repurchase and Cancellation Details - The board of directors approved the repurchase and cancellation of shares during the sixth board meeting on August 27, 2025, and the second extraordinary shareholders' meeting on October 16, 2025 [1] - The repurchase is a result of personal reasons for some holders leaving and others not achieving performance targets [1] - The repurchase price is set at 6.13 yuan per share, totaling 1.72 million yuan for the 281,500 shares [1] Group 2: Notification to Creditors - The company is notifying creditors about the capital reduction due to the share repurchase, allowing them to claim debts or request guarantees within specified timeframes [3] - Creditors have 30 days from receiving the notice or 45 days from the announcement date to assert their rights [3] - Required documentation for creditors includes contracts and proof of debt relationships, with specific requirements for both corporate and individual creditors [3][4] Group 3: Shareholder Meeting Resolutions - The second extraordinary shareholders' meeting held on October 16, 2025, approved several key resolutions, including the issuance of H shares and the related listing on the Hong Kong Stock Exchange [6][10] - All resolutions were passed with the required majority, including the repurchase of shares from the employee stock ownership plan [12][13] - The meeting was attended by all board members, with some participating via video conference [9]